共 50 条
- [11] Real-world evidence of outcomes of oligometastatic hormone-sensitive prostate cancer patients treated with metastasis-directed therapy [J]. PROSTATE, 2023, 83 (14): : 1365 - 1372
- [12] Clinical Outcomes with Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: Results from a Prospective Registry Trial [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E126 - E128
- [15] Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel [J]. FRONTIERS IN ONCOLOGY, 2022, 12
- [17] Response to letter to the editor regarding C Franzese et al. “Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer” [J]. Journal of Cancer Research and Clinical Oncology, 2022, 148 : 1003 - 1004
- [18] Prospective Longitudinal Assessment of Quality of Life and Symptoms in Patients With Oligometastatic Cancer Treated With Stereotactic Body Radiation Therapy: Analysis of a Phase 2 Trial [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E542 - E543
- [20] Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation [J]. Leukemia, 2011, 25 : 1587 - 1597